SLC52A3 Antibody, HRP conjugated

Code CSB-PA873618LB01HU
Size US$166
Order now
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Full Product Name
Rabbit anti-Homo sapiens (Human) SLC52A3 Polyclonal antibody
Uniprot No.
Target Names
SLC52A3
Alternative Names
bA371L19.1 antibody; BVVLS antibody; BVVLS1 antibody; C20orf54 antibody; C20orf54provided by HGNC antibody; Chromosome 20 open reading frame 54 antibody; hRFT2 antibody; member 3 antibody; MGC10698 antibody; RFT2 antibody; RFVT3 antibody; Riboflavin transporter 2 antibody; riboflavin transporter antibody; riboflavin transporter, member 3 antibody; S52A3_HUMAN antibody; Slc52a3 antibody; solute carrier family 52 (riboflavin transporter), member 3 antibody; Solute carrier family 52 antibody; solute carrier family 52, riboflavin transporter, member 3 antibody
Raised in
Rabbit
Species Reactivity
Human
Immunogen
Recombinant Human Solute carrier family 52, riboflavin transporter, member 3 protein (159-220AA)
Immunogen Species
Homo sapiens (Human)
Conjugate
HRP
Clonality
Polyclonal
Isotype
IgG
Purification Method
>95%, Protein G purified
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4
Form
Liquid
Tested Applications
ELISA
Protocols
Troubleshooting and FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Plasma membrane transporter mediating the uptake by cells of the water soluble vitamin B2/riboflavin that plays a key role in biochemical oxidation-reduction reactions of the carbohydrate, lipid, and amino acid metabolism. Humans are unable to synthesize vitamin B2/riboflavin and must obtain it via intestinal absorption.
Gene References into Functions
  1. The riboflavin transporter-3 (SLC52A3) 5'-flanking regions contain NF-kappaB p65/Rel-B-binding sites, which are crucial for mediating SLC52A3 transcriptional activity in esophageal squamous cell carcinoma (ESCC) cells. PMID: 29428966
  2. RFVT3 gene and protein expression levels were higher in DLD-1 and HT-29 compared to Caco2 cells. In tumor tissues of patients with CRC, RFVT3 gene expression levels were increased, while protein expression was reduced, with a small reduction in riboflavin amount. PMID: 29715086
  3. our knowledge, this is the first report to indicate that Rfvt3 contributes to placental riboflavin transport, and that disruption of Slc52a3 gene caused neonatal mortality with hyperlipidemia and hypoglycemia owing to riboflavin deficiency. PMID: 27272163
  4. This study found that RFT2 was overexpressed in glioma samples compared with normal brain tissue. PMID: 27584688
  5. RFVT3 is a target for posttranscriptional regulation by miR-423-5p in intestinal epithelial cells, and this regulation has functional consequences on intestinal riboflavin (RF) uptake process. PMID: 28912250
  6. Fourteen mutations in SLC52a3 were associated with Brown-Vialetto-Van Laere syndrome. PMID: 29053833
  7. SLC52A3 rs13042395 C>T polymorphism was associated with decreased cancer risk in the normal body mass index group, whereas no association was present in obesity group. PMID: 27600099
  8. Single nucleotide polymorphism rs13042395 in the SLC52A3 TT genotype carriers were likely to have reduced lymph node metastasis and longer relapse-free survival time. PMID: 27472962
  9. This study also identified a number of residues in the hRFVT-3 polypeptide that are important for its function/cell surface expression. PMID: 28637675
  10. RFT2 plays an important role in gastric carcinogenesis by modulating riboflavin absorption PMID: 26722538
  11. C20orf54 rs13042395 polymorphism was significantly associated with decreased ESCC and GCA risk especially for the subjects with under-weight or normal. PMID: 26154995
  12. A close association exists between functional SNP rs3746804 in C20orf54 and susceptibility to esophageal squamous cell carcinoma PMID: 25427582
  13. the single-nucleotide polymorphism rs13042395 in C20orf54 showed a significantly lower risk of esophageal squamous cell carcinoma in the younger age group but no significant association in the older group in a Korean population. PMID: 24152165
  14. Binding of Sp1 to the minimal SLC52A3 promoter. PMID: 25394472
  15. Increase in methylation of CpG 2 and CpG 3 in hRFT2gene promoter region is associated with the genesis of cervical squamous cell carcinoma. PMID: 24761851
  16. Results suggest that RFT2 contributes to esophageal squamous cell carcinoma tumorigenesis and may serve as a potential therapeutic target. PMID: 25045844
  17. C20orf54 expression were significantly up-regulated in CSCC. PMID: 24260322
  18. These results strongly suggest that RFVT3 would functionally be involved in riboflavin absorption in the apical membranes of intestinal epithelial cells PMID: 24264046
  19. Defective expression of C20orf54 is associated with the development of Kazak esophageal squamous cell carcinoma and this may represent a mechanism underlying the decreased plasma riboflavin levels in ESCC. PMID: 23275236
  20. RFT2 protein functional single nucleotide polymorphism might be associated with the development of esophageal squamous cell carcinoma. PMID: 22533825
  21. Identification of novel mutations that affect amino acid changes in Brown-Vialetto-Van Laere syndrome patients. PMID: 22718020
  22. Defective expression of RFT2 is associated with the development of gastric carcinoma and may result in decreased plasma riboflavin levels in GC. PMID: 22791947
  23. Single nucleotide polymorphism in C20orf54 gene is associated with esophageal squamous cell carcinoma. PMID: 22471455
  24. Mutations of riboflavin transporter-2 gene is associated with Brown-Vialetto-Van Laere syndrome. PMID: 22273710
  25. These results demonstrate a potential role for specific cysteine residues in the cell surface expression of riboflavin transporter 2 in human intestinal epithelial cells. PMID: 21512156
  26. results indicate that riboflavin transporter 2(RFT2) is a transporter involved in the epithelial uptake of riboflavin in the small intestine for its nutritional utilization PMID: 20724488
  27. Susceptibility loci at C20orf54 for esophageal squamous cell carcinoma. PMID: 20729853
  28. Discusses cloning of rat riboflavin transporter 2 and identification of a comparable protein in human. PMID: 19122205
  29. identified a candidate gene, C20orf54, in a consanguineous family with Brown-Vialetto-Van Laere syndrome with multiple affected individuals and subsequently demonstrated that mutations in this gene were the cause of disease in other, unrelated families PMID: 20206331

Show More

Hide All

Involvement in disease
Brown-Vialetto-Van Laere syndrome 1 (BVVLS1); Fazio-Londe disease (FALOND)
Subcellular Location
Apical cell membrane; Multi-pass membrane protein. Cell membrane.; [Isoform 1]: Cell membrane; Multi-pass membrane protein. Nucleus membrane; Multi-pass membrane protein. Cytoplasm.; [Isoform 2]: Cytoplasm.
Protein Families
Riboflavin transporter family
Tissue Specificity
Predominantly expressed in testis. Highly expressed in small intestine and prostate.
Database Links

HGNC: 16187

OMIM: 211500

KEGG: hsa:113278

STRING: 9606.ENSP00000217254

UniGene: Hs.283865

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*